Lumida
/VRDN
⌘K
Viridian Therapeutics Inc

Viridian Therapeutics Inc

VRDN
$21.24USD-4.71%-1.05 today

MARKET CAP

2.4B

P/E (TTM)

FWD P/E

DAY RANGE

$21 – $23

52W RANGE

$13
$34

AI Summary

Stalk
Sell NowMedium

VRDN has broken a key support cluster and entered a Stage 3 distribution context reinforced by the Support Failure pattern, establishing a bearish medium-term bias. Short-term momentum is confirming follow-through below the EMAs, making now an opportune time to sell into any relief rallies into the 23.10–23.30 resistance zone under the speculative strategy’s high-selectivity framework.

  • VRDN001 Phase III shows 75% proptosis response vs 44% for Tepezza
  • Q4 2023 cash of $613M sustains runway into mid-2026
  • Q1 2024 R&D spend at $50.7M vs $17.7M prior year escalates cash burn
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$3.0M$1.8M$314,000$302,000$70.8M
YoY %-40.2%-82.3%-3.8%+23359.9%
P / Sales79.5x516.1x3185.6x4309.2x37.2x
EV / Sales70.6x450.9x3012.3x4213.7x36.8x
Gross Profit, Adj.$3.0M$1.8M$314,000$302,000$70.8M
YoY %-40.2%-82.3%-3.8%+23359.9%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit70.6x450.9x3012.3x4213.7x36.8x
EBITDA, Adj.$-79.6M$-134.0M$-253.9M$-298.5M$-362.9M
YoY %-68.4%-89.4%-17.6%-21.6%
Margin %-2686.7%-7564.8%-80868.8%-98839.4%-512.3%
EV / EBITDA-2.6x-6.0x-3.7x-4.3x-7.2x
EBIT$-79.7M$-134.3M$-254.4M$-299.0M$-363.4M
YoY %-68.5%-89.5%-17.5%-21.5%
Margin %-2690.8%-7579.2%-81035.0%-99018.2%-512.9%
EV / EBIT-2.6x-5.9x-3.7x-4.3x-7.2x
Net Income$-79.4M$-87.0M$-175.0M$-208.6M$-281.9M
YoY %-9.6%-101.1%-19.2%-35.2%
Net Margin-2680.2%-4912.1%-55734.7%-69059.6%-397.9%
EPS (GAAP)-$6.66-$2.71-$3.91-$3.07-$3.32
YoY %+59.3%-44.3%+21.5%-8.1%